Tenrl Inhibitors
Chemical inhibitors of Tenrl can exert their inhibitory effects through various biochemical pathways by targeting different aspects of cellular signaling that are integral to Tenrl's function in RNA binding and regulation. Erlotinib, a known EGFR inhibitor, can impede the EGFR-mediated signaling pathways that may be essential for the proper functioning of Tenrl, thus indirectly leading to its inhibition. Similarly, mTOR is a central kinase in regulating protein synthesis, and the inhibition of mTOR by Rapamycin can result in a general downregulation of the protein synthesis machinery, which includes RNA-binding proteins like Tenrl. The PI3K/Akt pathway, targeted by LY294002 and Wortmannin, is another critical signal transduction route that plays a pivotal role in various cellular processes, including those involving RNA. By inhibiting PI3K, these compounds can suppress the downstream signaling required for Tenrl's activity in RNA metabolism.
The MAPK/ERK and p38 MAPK pathways, inhibited by U0126 and SB203580 respectively, are known to influence RNA binding protein activities. The inhibition of these pathways can alter the phosphorylation states of proteins, potentially disrupting the activation state necessary for Tenrl to bind and regulate its RNA targets. SP600125, which targets JNK, can disrupt transcription factor activity and mRNA stability, pathways in which Tenrl is likely involved, leading to its functional inhibition. KN-93 and Bisindolylmaleimide I, which target CaMKII and PKC respectively, can interfere with mRNA processing and splicing. Since Tenrl is presumed to be involved in these processes, the inhibition of CaMKII and PKC can affect Tenrl's interaction with RNA molecules. Additionally, Go6983 and Ro-31-8220, both broad-spectrum PKC inhibitors, can impede the phosphorylation of proteins within pathways critical for the RNA-related roles of Tenrl, thereby inhibiting its functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor. Since Tenrl is a protein involved in RNA binding and EGFR signaling can influence RNA-binding protein activity, the inhibition of EGFR by Erlotinib could lead to a decrease in Tenrl activity by reducing the EGFR-mediated signaling that may be necessary for Tenrl function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor which could indirectly inhibit Tenrl by reducing the overall protein synthesis machinery in the cell, thereby potentially decreasing the functional protein interactions that Tenrl requires for its RNA binding and regulatory functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. Given that PI3K is upstream of many RNA processing and translation pathways, inhibition by LY294002 could suppress the signaling required for Tenrl function in RNA metabolism. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. The MAPK/ERK pathway can influence RNA-binding protein activities, and by inhibiting this pathway, U0126 could impede the phosphorylation and activation states that may be required for Tenrl function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, and since p38 MAPK can affect RNA stability and translation, its inhibition could alter the cellular environment in a way that hampers Tenrl's ability to bind and regulate RNA. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can impact transcription factors and mRNA stability. By inhibiting JNK, SP600125 could disrupt the signaling necessary for Tenrl's involvement in RNA metabolism, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, and its action could result in the downregulation of cellular pathways that affect the RNA binding and regulatory functions of Tenrl, thereby inhibiting its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor distinct from U0126. By blocking MEK, PD98059 could prevent the activation of downstream proteins that may be critical for the RNA-related functions of Tenrl, resulting in its inhibition. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII). CaMKII influences various cellular processes including mRNA processing. Inhibition by KN-93 could affect the pathways that are potentially required for Tenrl's role in RNA dynamics. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a protein kinase C (PKC) inhibitor. PKC is involved in modulating RNA splicing and transport, processes in which Tenrl could be involved. Inhibition of PKC could therefore inhibit Tenrl's functional interaction with RNA molecules. | ||||||